Latham acts for Baxter on latest pharma acquisition as HSF picks up new client Claris

Herbert Smith Freehills (HSF) and Latham & Watkins won lead roles on Baxter International’s acquisition of Claris Injectables for $625m, in a bid by Baxter to expand its portfolio of essential generic injectable medicines. HSF represented Claris, while Latham acted for Baxter.

Continue reading “Latham acts for Baxter on latest pharma acquisition as HSF picks up new client Claris”